Who invested in Gelesis

7 rounds we have observed, with the one investor named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$170Mraised across 7 rounds since 2008, from 7 sources

$16MSeries A$3.6MVenture$2.6MVenture$12MSeries E$22MGrowth$30MRound$84MRound

Latest round: Round, $84MDec 2019
Step-upi: 2.8×
Investors: 1

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

200820102012201420162018

$16MSeries A$3.6MVenture$2.6MVenture$12MSeries E$22MGrowth$30MRound$84MRound

First round: Series A, $16M
Biggest round: $84M
Usual gap between rounds: 2.9 years

The rounds

Dec 2019
Round$84M1 new
- Vitruvian Partners
Reported by FinSMEs
Mar 2018
Round$30M
No investor was named in the report.
Reported by FinSMEs
Mar 2015
Growth$22M
No investor was named in the report.
From a historical funding record
May 2014
Series E$12M
No investor was named in the report.
From a historical funding record
Jun 2011
Venture$2.6M
No investor was named in the report.
Reported by masshightech.comSEC filing: $2.6M sold, first sale May 2011
May 2011
Venture$3.6M
No investor was named in the report.
Reported by masshightech.comSEC filing: $3.6M sold, first sale Apr 2011
Jan 2008
Series A$16M
No investor was named in the report.
Reported by masshightech.com

Founders and team

From the SEC filings it signed: 2 on the team.

Yishai ZoharDirector, President, and Chief Executive Officeri
Elliot MaltzTreasureri

On the board, as filediElon BomsJohn LaMattinaMeghan FitzgeraldRobert Forrester

Everyone who backed them

Vitruvian PartnersVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 3 firms list Gelesis as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.